Clinical trials: Alcoholic Hepatitis, active
Autoimmune Hepatitis, Primary Sclerosing Cholangitis
Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome
In this study, we aim to identify gut microbiomes specific to patients with chronic refractory liver disease and to conduct a gut-liver axis study on the pathogenesis and disease progression.
- Conditions
- Autoimmune Hepatitis, Primary Sclerosing Cholangitis, Non-Alcoholic Fatty Liver Disease, Liver Abscess
- Trial name
- LGAS (NCT06519162)
- Where
- South Korea
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Chungnam National University Hospital
Liver Cirrhosis
Faecal Microbiota Transplantation for Liver Cirrhosis
The purpose is to investigate the effect of faecal microbiota transplantation (FMT) on complications, progression, and mortality of patients with liver cirrhosis.
- Trial name
- CHiFT (NCT04932577)
- Testing
- Faecal microbiota transplantation
- Where
- Denmark
- Volunteers
- 220 people
- Sponsor
- University of Aarhus
Non-Alcoholic Steatohepatitis(NASH), Hepatitis C
Blood Collection Biorepository for Liver Disease Research
The purpose of establishing a biorepository is to provide high quality specimens (serum, plasma, buffy coat and liver tissue) for future researchers who are studying the effects that fatty liver and viral diseases have on the…
- Conditions
- Non-Alcoholic Steatohepatitis(NASH), Hepatitis C, Hepatitis B, Fibrosis
- Trial name
- NCT03025074
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- State University of New York at Buffalo
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)
This study will test a Regeneron study drug called ALN-CIDEB to find out whether it may help treat a liver disease called MASH. In this study, researchers are looking at the effect of ALN-CIDEB on reducing liver fat, liver…
- Trial name
- NCT07631637
- Testing
- ALN-CIDEB
- Where
- 16 sites in United States, Puerto Rico
- Volunteers
- 150 people
- Sponsor
- Regeneron Pharmaceuticals
Hepatitis
Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)
The primary purpose of this study is to evaluate the safety and efficacy of larsucosterol, as determined by transplant-free survival through Day 90 in participants with severe alcohol-associated hepatitis (AH) with pre-treatment…
- Trial name
- NCT07428538
- Testing
- Larsucosterol
- Where
- 92 sites in United States
- Volunteers
- 350 people
- Sponsor
- Bausch Health Americas, Inc.
Autoimmune Hepatitis, Non-Alcoholic Fatty Liver Disease
Molecular Characterization of Autoimmune Hepatitis: A Lipidomic Approach
This is a two-arm, prospective, controlled observational pilot clinical study aimed at characterizing the lipidomic profile and extracellular vesicles (EVs) of patients with autoimmune hepatitis (AIH) compared to patients with…
- Trial name
- AIH-LIPID (NCT07644936)
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Chronic Hepatitis B, Nonalcoholic Fatty Liver Disease
Follow-up of Chronic Hepatitis B Patients With Comorbid Nonalcoholic Fatty Liver Disease
The purpose of this study is to determine the disease progression in CHB/NAFLD compared with CHB and NAFLD including liver cirrhosis, cirrhotic complications and hepatocellular carcinoma (HCC).
- Trial name
- NCT02863757
- Where
- China
- Volunteers
- 1,500 people
- Sponsor
- Humanity and Health Research Centre
Alcohol Use Disorder, Alcohol-associated Liver Disease
Financial Rewards for Reducing Alcohol Use in Patients With Liver Disease
This study tests whether providing financial rewards based on a blood test result can help people with alcohol-associated liver disease (ALD) stop or reduce their drinking.
- Conditions
- Alcohol Use Disorder, Alcohol-associated Liver Disease, Liver Cirrhosis, Alcoholic, Alcohol-Associated Hepatitis
- Trial name
- REINFORCE (NCT07465588)
- Testing
- PEth Based Contingency Management, PEth Monitoring with Fixed Incentives
- Volunteers
- 90 people
- Sponsor
- Massachusetts General Hospital
Alcoholic Hepatitis, Acute Alcoholic Hepatitis
MRG-001 in Patients With Alcoholic Hepatitis
The goal of this study is to test MRG-001 (an experimental medication). The purpose of this trial is to assess the dose related safety, Pharmacokinetics, and Pharmacodynamics of MRG-001 in patients with severe alcoholic hepatitis…
- Trial name
- NCT06307522
- Testing
- MRG-001
- Volunteers
- 32 people
- Sponsor
- MedRegen LLC
Alcoholic Hepatitis (AH)
Recompensation in Alcohol Related Hepatitis
Genetic activity and metabolic changes may be part of the pathogenesis in alcohol related hepatitis. We do not know exactly how alcohol cessation affects liver functions and metabolism.
- Trial name
- A-HEP (NCT06740318)
- Testing
- Motivational enhancement therapy
- Where
- Denmark
- Volunteers
- 160 people
- Sponsor
- Nina Kimer
Severe Alcoholic Hepatitis
LiverTREM-1: Hepatic TREM-1 Expression and Prognosis in Severe Alcoholic Hepatitis
Background \& Rationale Severe alcohol-related hepatitis (SAH) is a serious condition with a 3-month mortality rate of ~30%. Diagnosis and prognosis are complex due to non-specific and insensitive clinical, biological, and…
- Trial name
- Liver TREM-1 (NCT07176741)
- Testing
- TREM-1 expression (via immunohistochemistry) between SAH patients and controls
- Volunteers
- 300 people
- Sponsor
- Central Hospital, Nancy, France
Alcoholic Hepatitis
PROlonged Corticosteroid Treatment or N-ACetylcysteine for Severe Alcoholic Hepatitis
Only patients suffering from a severe form of alcoholic hepatitis (Maddrey's discriminant function greater than 32) require medical treatment.
- Trial name
- PROCORNAC (NCT06956482)
- Testing
- N-Acetylcysteine (NAC) Treatment, Prednisolone, Prednisolone 10mg
- Where
- France
- Volunteers
- 477 people
- Sponsor
- University Hospital, Lille
Carcinoma, Hepatocellular, Hepatitis C, Chronic
Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)
The goal of this study is to evaluate whether the standardized liver cancer risk stratification management can effectively improve the early diagnosis rate of liver cancer in the targeted risk population in China.
- Conditions
- Carcinoma, Hepatocellular, Hepatitis C, Chronic, Hepatitis B, Chronic, Cirrhosis, Liver
- Trial name
- dSEARCH (NCT05870969)
- Testing
- Liver cancer surveillance every 3 months, Liver cancer surveillance every 6 months, Liver cancer surveillance annually
- Where
- China
- Volunteers
- 20,000 people
- Sponsor
- Ruijin Hospital
Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-Alcoholic Steato-Hepatitis (NASH)
How Abnormal Function of Fat Tissue in Type 1 Diabetes Contributes to Fat in the Liver
Steatotic liver disease associated with metabolic dysfunction (MASLD) is a disease caused by excess fat storage in the liver. Excessive fat delivery to the liver and MASLD typically occurs in people with abdominal obesity and…
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-Alcoholic Steato-Hepatitis (NASH), Type 1 Diabetes Mellitus
- Trial name
- AGL14 (NCT07133854)
- Testing
- Imaging PET/MRI, Stable isotope infusions, meal test
- Where
- Canada
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Université de Sherbrooke
Alcohol Use Disorder, Alcoholic Hepatitis
Alcohol Treatment Outcomes Following Early vs. Standard Liver Transplant for SAH
Given the severe consequences of alcohol relapse following liver transplantation for alcoholic hepatitis (AH-LT), it is critical to accurately identify alcohol use and implement alcohol interventions early in the post-transplant…
- Trial name
- NCT03845205
- Testing
- Integrated AUD Treatment
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Johns Hopkins University
Alcoholic Hepatitis, Alcohol-related Liver Disease
Investigating HepQuant DuO Test as a Biomarker in Alcohol-related Liver Disease
This is a study to measure liver recovery in patients with recent alcohol-associated liver injury by assessing liver function and physiology using HepQuant DuO.
- Trial name
- NCT07060547
- Testing
- HepQuant DuO Test
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- HepQuant, LLC
Chronic Hepatitis b, Non-alcoholic Fatty Liver Disease
Risk Factors for Hepatic Inflammation, Fibrosis and Prognosis in Patients With CHB and NAFLD
Chronic hepatitis B (CHB) affects an estimated 292 million people, and causes approximately 800,000 people deaths per year from liver-related complications including cirrhosis and hepatocellular carcinoma, remaining a major…
- Trial name
- NCT05766449
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
NASH With Fibrosis, Diabete Type 2
Non-invasive Tests for Non-alcoholic Steato-hepatitis
The main objective is to study and validate a new approach for NASH and liver fibrosis diagnosis and personalized follow-up based on monocyte biomarkers and plasma metabolites.
- Conditions
- NASH With Fibrosis, Diabete Type 2, Obesity
- Trial name
- TEIRESEAS (NCT07502755)
- Testing
- Administration of Deuterated water
- Where
- Italy
- Volunteers
- 828 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Cirrhosis, Alcoholic Liver Disease
Intra-Hepatic Microbiota in Alcoholic Hepatitis
Alcoholic hepatitis (AH) is a serious complication of alcoholic liver disease (ALD). The histological presentation of AH is characterized by neutrophilic lobular inflammation, macrovesicular steatosis, hepatocyte ballooning and…
- Conditions
- Cirrhosis, Alcoholic Liver Disease, Alcoholic Hepatitis
- Trial name
- HepMAH (NCT06307964)
- Testing
- Biological sampling
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Hospices Civils de Lyon
Alcoholic Liver Disease, Severe Alcoholic Hepatitis
Study of Genetic Determinants in Alcoholic Hepatitis and Establishment of a Multicenter Prospective Cohort of Patients With Alcoholic Liver Disease
Alcoholic hepatitis carries a risk of high mortality at short term, especially in its severe form. Its diagnosis is confirmed by liver biopsy.
- Conditions
- Alcoholic Liver Disease, Severe Alcoholic Hepatitis, Alcoholic Cirrhosis
- Trial name
- COMADHAA (NCT04106518)
- Where
- 9 sites in France
- Volunteers
- 447 people
- Sponsor
- University Hospital, Lille